Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
gptkb:Actinium-225
gptkb:Lutetium-177 |
| gptkbp:associatedWith |
gptkb:Pluvicto
|
| gptkbp:bindingTarget |
gptkb:PSMA
|
| gptkbp:CASNumber |
1613121-53-6
|
| gptkbp:category |
radiopharmaceutical
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:ABX_GmbH
|
| gptkbp:firstDescribed |
2015
|
| gptkbp:hasMolecularFormula |
C49H72N10O9
|
| https://www.w3.org/2000/01/rdf-schema#label |
PSMA-617
|
| gptkbp:indication |
metastatic castration-resistant prostate cancer
|
| gptkbp:license |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
binds to PSMA on prostate cancer cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:synonym |
PSMA ligand
|
| gptkbp:target |
prostate-specific membrane antigen
|
| gptkbp:usedFor |
prostate cancer
|
| gptkbp:usedIn |
radioligand therapy
|
| gptkbp:bfsParent |
gptkb:Endocyte
|
| gptkbp:bfsLayer |
5
|